Fortress Biotech, Inc. (FBIO) stock

FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/30

$1.88−0.11 (-5.53%)

Close on Nov 13, 2026Market cap $69.14MP/E –Yield –

Fortress Biotech price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Fortress Biotech's price to sales ratio was 1.0× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.2× to 3.8×, with a median of 1.1×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	1.0×	−0.8
2025	Dec 31, 2025	1.8×	+0.9
2024	Dec 31, 2024	0.9×	+0.6
2023	Dec 29, 2023	0.3×	−0.6
2022	Dec 30, 2022	0.9×	−2.9
2021	Dec 31, 2021	3.8×	−3.1
2020	Dec 31, 2020	6.9×	+1.7
2019	Dec 31, 2019	5.2×	+3.3
2018	Dec 31, 2018	1.9×	−6.5
2017	Dec 29, 2017	8.4×	−23.0
2016	Dec 30, 2016	31.4×	−219.1
2015	Dec 31, 2015	250.5×	–

Where these numbers come from

Parsed from the XBRL in Fortress Biotech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Oct 10, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing